Causeway Sensors is leading a £422k consortium that aims to demonstrate the capabilities of TITAN (our bioprocess sensor platform) in so-called downstream operations to enhance process efficiency and sustainability, ultimately improving drug quality and lowering the cost of therapies.

Fusion Antibodies are testing the Causeway Sensors TITAN biosensor system as part of our Innovate UK funded project to strengthen the regional ability to manufacture the complex building blocks required for modern medicines production.

Causeway is delighted to announce the launch of a £98k funded research project with Innovate UK, strengthening our understanding of and ability to manufacture the complex biochemical building blocks needed to create a locally-sourced supply chain for our cutting-edge, beachhead system, TITAN.